September 09, 2026

Where AI is already paying off in drug development

Pharmaceutical leaders point to faster manufacturing, smarter antibody design, and deeper data analysis.

MDSpire News

September 08, 2026

Cognitive decline emerges as next front in 9/11 care

As the WTC Health Program population passes age 60, clinicians are tracking a rise in impairment that doesn't match the usual pattern of Alzheimer's disease.

MDSpire News

September 08, 2026

JIA risk may be linked to pregnancy factors

Investigators followed 78,901 offspring using pregnancy and national registry data through 2023.

MDSpire News

September 08, 2026

CD19 CAR T Therapy Tested in Refractory Rheumatoid Arthritis

Disease activity fell in all six participants in a phase I trial, with three achieving sustained drug-free remission during follow-up

The Medicine Maker

September 04, 2026

Inside the hip osteoarthritis microbiome

Investigators compared intra-articular microbial profiles and predicted metabolic pathways in patients with hip osteoarthritis and nonarthritic controls.

MDSpire News

September 03, 2026

Google clinical leader on health care’s AI ‘epistemic shift’

“AI is in its infancy. It’s as bad as it will ever be right now, and the rate of change is remarkable.”

MDSpire News

September 01, 2026

What happens to clinical skills when AI does the routine work?

“The need to be extra vigilant when you're reviewing something versus doing it from scratch can be a real problem.”

MDSpire News

September 01, 2026

JIA-Associated Uveitis in Adults

Ophthalmologists caring for adults with this condition may encounter persistent inflammation, treatment dependence, and the cumulative ocular effects of childhood disease.

Retinal Physician

September 01, 2026

Optimizing Corticosteroid Therapy in Uveitis

Multiple corticosteroid approaches are available for the management of noninfectious uveitis, including injectable triamcinolone, sustained-release dexamethasone implants, and fluocinolone implants. The optimal choice depends on disease location, desired duration of effect, treatment burden, lens status, and tolerance for potential adverse effects such as cataract progression and elevated intraocular pressure (IOP).

Retinal Physician

September 01, 2026

Updates in Uveitis and Ocular Oncology

Upfront: Monthly reflection by Editor in Chief Diana V. Do, MD.

Retinal Physician